H. Lundbeck A/S (HLUN B)

H. Lundbeck is a Danish specialty pharmaceutical firm focused almost entirely on brain health. Its portfolio targets psychiatric and neurological conditions such as depression, schizophrenia, Alzheimer’s and Parkinson’s disease. The company develops and commercializes branded CNS medicines for patients and specialists worldwide, with research and manufacturing rooted in neuroscience rather than broad primary-care pharma.

Market

Copenhagen

Sector

Healthcare

Trend

Uptrend

Last close

44.12 (-0.59% on the day)

MA50

42.32

MA200

41.49

52-week range

35.86–45.91

Market cap

41.1B DKK

P/E

10.33

Dividend yield

2.75%

Data as of

2026-09-04

All markets — KeepWinning global stock screener

Other companies on Copenhagen: H. Lundbeck A/S (HLUN A), FLSmidth & Co. A/S (FLS), Alm. Brand A/S (ALMB), Zealand Pharma A/S (ZEAL), TORM plc (TRMD A), Royal Unibrew A/S (RBREW)